These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28809532)

  • 41. Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer.
    Liu Y; Tiruthani K; Wang M; Zhou X; Qiu N; Xiong Y; Pecot CV; Liu R; Huang L
    Nanoscale Horiz; 2021 Apr; 6(4):319-329. PubMed ID: 33587080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
    Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Local and transient gene expression primes the liver to resist cancer metastasis.
    Goodwin TJ; Zhou Y; Musetti SN; Liu R; Huang L
    Sci Transl Med; 2016 Nov; 8(364):364ra153. PubMed ID: 27831902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
    Jindal V; Arora E; Masab M; Gupta S
    Med Oncol; 2018 May; 35(6):84. PubMed ID: 29728788
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
    Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
    Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
    Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
    Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
    Chen Q; Xu L; Chen J; Yang Z; Liang C; Yang Y; Liu Z
    Biomaterials; 2017 Dec; 148():69-80. PubMed ID: 28968536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
    Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
    Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
    [No Abstract]   [Full Text] [Related]  

  • 53. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
    Fallon JK; Vandeveer AJ; Schlom J; Greiner JW
    Oncotarget; 2017 Mar; 8(13):20558-20571. PubMed ID: 28423552
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 57. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
    Chen YP; Zhang Y; Lv JW; Li YQ; Wang YQ; He QM; Yang XJ; Sun Y; Mao YP; Yun JP; Liu N; Ma J
    Theranostics; 2017; 7(14):3585-3594. PubMed ID: 28912897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia.
    Jing W; Gershan JA; Holzhauer S; Weber J; Palen K; McOlash L; Pulakanti K; Wesley E; Rao S; Johnson BD; Riese MJ
    Cancer Res; 2017 Oct; 77(20):5676-5686. PubMed ID: 28916658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
    Noguchi T; Ward JP; Gubin MM; Arthur CD; Lee SH; Hundal J; Selby MJ; Graziano RF; Mardis ER; Korman AJ; Schreiber RD
    Cancer Immunol Res; 2017 Feb; 5(2):106-117. PubMed ID: 28073774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.